Robert Langland Eil MD
Hepatobiliary Surgery, Pancreas, Surgical Oncology (Other than Breast), Minimally Invasive Surgery
Assistant Professor of Surgery & Cell, Developmental, and Cancer Biology
Join to view full profile
3181 SW Sam Jackson RoadPortland, OR 97239
Phone+1 503-494-5501
Dr. Eil is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Robert Eil is a general surgeon based in Portland, OR, with subspecialties in hepatobiliary surgery, pancreatic surgery, surgical oncology (excluding breast), and minimally invasive surgery. He completed fellowships in tumor immunology at the National Cancer Institute and complex general surgical oncology at Memorial Sloan Kettering Cancer Center. His surgical residency was at Oregon Health & Science University, where he is currently an Assistant Professor and Surgery Resident. Dr. Eil has published several research articles, focusing on topics such as pancreatic cancer, colorectal liver metastases, and immune responses in cancer treatment.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Complex General Surgical Oncology, 2018 - 2020
Oregon Health & Science University (OHSU Health)Residency, Surgery, 2016 - 2018
National Cancer InstituteFellowship, Tumor Immunology, 2013 - 2016- Oregon Health & Science University (OHSU Health)Residency, Surgery, 2010 - 2013
University of North Carolina at Chapel Hill School of MedicineClass of 2010
Certifications & Licensure
OR State Medical License 2013 - 2027
NY State Medical License 2017 - 2021
American Board of Surgery Surgery- American Board of Surgery Complex General Surgical Oncology
Publications & Presentations
PubMed
- Increased Glucose Availability Sensitizes Pancreatic Cancer to Macrophage-Targeting Immunotherapies.Jonathan J Hue, Mehrdad Zarei, Priyashree Sunita, Sami O Abul-Khoudoud, Goutam Dey
Cancer Research Communications. 2026-06-01 - CAR T-Cell Therapy for Solid Tumors: Clinical Challenges and Current Advancements.Anthony Gutierrez, Robert Eil
Surgical Oncology Clinics of North America. 2026-04-01 - Interleukin 6 Drives Durable T Cell-Mediated Immunity to Pancreatic Cancer.Paige C Arneson-Wissink, Alexandra Q Bartlett, Heike Mendez, Xinxia Zhu, Peter R Levasseur
Cellular and Molecular Gastroenterology and Hepatology. 2026-01-01
Press Mentions
OHSU Scientists Awarded Funding for Innovative Human Health ResearchFebruary 3rd, 2025
Grant Support
- Targeting an unrecognized checkpoint on T cell function in tumorsOREGON HEALTH & SCIENCE UNIVERSITY2021–2026
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
